Cardiovascular Sciences, Inc. Agrees to Terms With the University of Central Florida

ORLANDO, FL announced today that following the recent funding event, the Company has been able to reach an agreement with the University of Central Florida to continue the Company's research and development on its post-surgical anti-adhesion technology. Adhesions occur after surgery when two normally separate but adjacent tissues that have been injured or stressed scar together. Adhesions are part of the normal healing process, but when they occur between tissues that are not normally attached, problems ranging from mild discomfort to life threatening intestinal obstruction can occur. The global market to address the problem of adhesions and adhesion related complications exceeds $6 billion.

To this point, the collaboration between Cardiovascular Sciences, Inc. and UCF has produced a second-generation material with physical properties which appear to have exceeded the initially designed criteria. At surgery, this material is placed over and between areas likely to produce adhesions and are gradually degraded and resorbed by the body after the period in which adhesions are likely to occur, has passed. This next phase in the Company's development will involve several areas of investigation. One will be to devise methods to manipulate the physical characteristics of the material in order to broaden the range of indications in which the material will be useful. A second will be to expand the animal trials beyond the proof-of-concept phase so that data can be gathered to support the requirements to bring this product to market, first in the veterinary arena and on to use in human clinical medicine.

Physician and company CEO, Larry Hooper, exclaims, "The further we have come in this development, the increased number of potential uses and indications we have encountered. We have received several inquiries from fields we never expected, expressing to us additional proposed uses for our technology in areas we did not have in mind when we started."

Cardiovascular Sciences, Inc. has offices located in the Research Park adjacent to the UCF campus and is a client company of the award winning UCF High Tech Incubator program. Gordon Hogan, the Incubator's Business Development Executive, is quick to praise, "It is exciting to watch Cardiovascular Sciences leverage their existing management strengths with the scientific and technological strengths of UCF. This convergence can easily result in dramatic changes in the prevention of surgical adhesions."

About Cardiovascular Sciences, Inc.

Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals.

The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well.

In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development.

Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.

For more information contact: Cardiovascular Sciences Investor Relations 800-858-7502 [e-mail]